Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBT Margin (2017 - 2026)

Neurocrine Biosciences filings provide 15 years of EBT Margin readings, the most recent being 29.72% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 382.0% to 29.72% in Q4 2025 year-over-year; TTM through Dec 2025 was 24.66%, a 403.0% increase, with the full-year FY2025 number at 24.66%, up 403.0% from a year prior.
  • EBT Margin hit 29.72% in Q4 2025 for Neurocrine Biosciences, down from 36.71% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 38.47% in Q4 2023 to a low of 116.5% in Q2 2022.
  • Median EBT Margin over the past 5 years was 21.54% (2021), compared with a mean of 10.88%.
  • Biggest five-year swings in EBT Margin: crashed -13640bps in 2022 and later soared 14336bps in 2023.
  • Neurocrine Biosciences' EBT Margin stood at 4.42% in 2021, then surged by 747bps to 28.62% in 2022, then surged by 34bps to 38.47% in 2023, then crashed by -33bps to 25.9% in 2024, then rose by 15bps to 29.72% in 2025.
  • The last three reported values for EBT Margin were 29.72% (Q4 2025), 36.71% (Q3 2025), and 23.2% (Q2 2025) per Business Quant data.